Weight-Loss drug may change how birth control works

NCT ID NCT07523711

Recruiting now Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Apr 14, 2026 · Last updated May 08, 2026 · Updated 5 times

Summary

This early-stage study looks at how a new weight-loss drug, maridebart cafraglutide (AMG 133), changes the way the body processes oral contraceptives. It involves 45 postmenopausal women aged 45 to 65 who are overweight or obese. The goal is to see if the drug affects birth control hormone levels, which could impact contraceptive effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fortrea Clinical Research Unit - Dallas
RECRUITING

Dallas, Texas, 75247-4968, United States
Fortrea Clinical Research Unit - Daytona Beach
RECRUITING

Daytona Beach, Florida, 32117-5116, United States
Fortrea Clinical Research Unit Inc. - Madison
RECRUITING

Madison, Wisconsin, 53704-2526, United States

Conditions

Explore the condition pages connected to this study.

OBESITY OVERWEIGHT